Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting

European Heart Journal

Volumn 34, Issue 46, 2013, Pages 3557-3562

  Angeloni, Emiliano ^a   Paneni, Francesco ^b   Landmesser, Ulf ^c   Benedetto, Umberto ^a   Melina, Giovanni ^a   Lüscher, Thomas Felix ^c   Volpe, Massimo ^b,d   Sinatra, Riccardo ^a   Cosentino, Francesco ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cardiovascular mortality; Coronary artery bypass grafting; Dysfunctional HDL C; Secondary prevention

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; ELECTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SECONDARY PREVENTION;

CARDIOVASCULAR MORTALITY; CORONARY ARTERY BYPASS GRAFTING; DYSFUNCTIONAL HDL-C; SECONDARY PREVENTION;

AGED; CHOLESTEROL, HDL; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; SECONDARY PREVENTION; SURGICAL PROCEDURES, ELECTIVE;

EID: 84887861072     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht163     Document Type: Article

References (26)

1. Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundstrom J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, D'Agostino RB Sr, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, Gomez-de-la-Camara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J. Lipid-related markers and cardiovascular disease prediction. JAMA 2012; 307: 2499-2506.
2. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, BittnerV, Fruchart JC.HDLcholesterol, very low levels of LDLcholesterol, and cardiovascular events. N Engl J Med 2007;357: 1301-1310. (Pubitemid 47481452)
3. Arsenault BJ, Barter P, DeMicco DA, BaoW, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H,Wenger NK, Shepherd J,Waters DD, Kastelein JJ. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol 2011;57: 63-69.
4. Assmann G, Nofer Jr. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003;54: 321-341. (Pubitemid 37386400)
5. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004;95: 764-772. (Pubitemid 39390578)
6. Besler C, Luscher TF, Landmesser U. Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 2012;4: 251-268.
7. Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat Rev Cardiol 2009;6: 455-463.
8. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108: 2751-2756. (Pubitemid 37498976)
9. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller M, Akhmedov A, Daniil G, Manes C, Templin C, Wyss C, Maier W, Tanner FC, Matter CM, Corti R, Furlong C, Lusis AJ, von Eckardstein A, Fogelman AM, Lüscher TF, Landmesser U. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011;121: 2693-2708.
10. Sorrentino SA, Bahlmann FH, Besler C, Muller M, Schulz S, Kirchhoff N, Doerries C, Horvath T, Limbourg A, Limbourg F, Fliser D, Haller H, Drexler H, Landmesser U. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2007;116: 163-173. (Pubitemid 47057522)
11. Charakida M, Besler C, Batuca JR, Sangle S, Marques S, Sousa M, Wang G, Tousoulis D, Delgado Alves J, Loukogeorgakis SP, Mackworth-Young C, D'Cruz D, Luscher T, Landmesser U, Deanfield JE. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009;302: 1210-1217.
12. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2010;30: 151-155.
13. Patel PJ, KheraAV, Jafri K, Wilensky RL, Rader DJ. The anti-oxidative capacity of highdensity lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 2011;58: 2068-2075.
14. Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 2007;356: 1364-1366. (Pubitemid 46513305)
15. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute;American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120: 1640-1645.
16. Blackstone EH. Comparing apples and oranges. J Thorac Cardiovasc Surg 2002;123: 8-15.
17. Stevens LA, Coresh J, GreeneT, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006;354: 2473-2483. (Pubitemid 43855050)
18. Mineo C,Deguchi H, Griffin JH, ShaulPW. Endothelial and antithrombotic actions of HDL. Circ Res 2006;98: 1352-1364. (Pubitemid 43948059)
19. Khera AV, Cuchel M, de la Llera-MoyaM, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.NEngl J Med 2011;364: 127-135.
20. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horvath T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010;121: 110-122.
21. Besler C, Heinrich K, Riwanto M, Luscher TF, Landmesser U. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Curr Pharm Des 2010;16: 1480-1493.
22. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365: 2255-2267.
23. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357: 2109-2122. (Pubitemid 350146106)
24. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367: 2089-2099.
25. Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Munzel T, Kastelein JJ, Deanfield JE. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012;33: 857-865.
26. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378: 1547-1559.